Perosphere is a specialty pharmaceutical company with internationally recognized drug delivery expertise.

Feature

John Laragh

We extend our deepest condolences to the family, friends and colleagues of our esteemed advisor and friend John H. Laragh, MD. Dr. Laragh has served on our advisory board since Perosphere’s inception and will be genuinely missed. An excellent summary of Dr. Laragh’s many accomplishments, including his tremendous impact on the field of Hypertension, may be found here: John H. Laragh, MD: Clinician-Scientist

 

Latest News

02Apr2015 Perosphere Receives FDA Fast Track Designation for Investigational Anticoagulant Reversal Agent PER977
09Mar2015 Perosphere to Present Investigational Broad-Spectrum Anticoagulant Reversal Agent PER977 Data at American College of Cardiology (ACC) 64th Annual Scientific Sessions
15Nov2014 Perosphere Presents Data on Investigational Anticoagulant Reversal Agent PER977 at 2014 American Heart Association (AHA) Annual Scientific Sessions in Chicago
05Nov2014 Perosphere’s Broad-Spectrum Anticoagulant Reversal Agent Clinical Trial Results Published in Published in the New England Journal of Medicine
23Oct2014 Perosphere Pharmaceutical Manufacturing Ribbon-Cutting
06Oct2014 Perosphere and Daiichi Sankyo Enter into a Clinical Trial
Collaboration Agreement for Phase 3 Studies of PER977 to
Investigate Reversal of the Anticoagulant Activity of the
Investigational Factor Xa-Inhibitor Edoxaban
25Apr2013 Perosphere and Daiichi Sankyo Enter into a Clinical Trial Agreement to Evaluate the Efficacy and Safety of PER977 to Reverse the Anticoagulant Activity of the Investigational, Oral, Once-Daily Factor Xa Inhibitor Edoxaban
21Dec2012 Perosphere Advisory Board Chairman, Professor Robert Langer, Wins the National Medal of Technology

Presentations & Publications

The

NEW ENGLAND JOURNAL ofMEDICINE

Perosphere’s Broad-Spectrum Anticoagulant Reversal Agent Clinical Trial Results Published in The New England Journal of Medicine read more...